Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies Corp (NASDAQ:ADPT), executed a series of stock transactions between March 19 and March 23, 2026, that included both open-market sales and option exercises.
Under a prearranged 10b5-1 trading plan, Rubinstein sold a total of 57,180 shares of common stock. Sale prices ranged from $13.18 to $13.83 per share, and the aggregate gross proceeds from those dispositions amounted to $769,642. At the time the trades were reported, ADPT was quoted at $13.66 per share, a level that represents a roughly 63% return over the past 12 months even as the stock has declined almost 16% so far year to date.
The insider activity also included the exercise of stock options. Rubinstein exercised options to acquire 43,166 shares of Adaptive Biotechnologies common stock. The option strike prices fell between $6.55 and $7.27, and the total value associated with those exercises was $307,650.
Company performance and analyst reaction
Adaptive Biotechnologies reported fourth-quarter 2025 results that outpaced consensus estimates. The company posted earnings per share of -$0.09, better than the -$0.18 forecast. Revenue for the quarter reached $71.7 million, ahead of the $59.33 million analysts had expected, a beat of 20.85%.
Following those results, several brokerages adjusted their outlooks. BTIG raised its price target on Adaptive Biotechnologies to $22.00, citing robust expansion in the company’s core Minimal Residual Disease, or MRD, business, which grew 54% year over year in the fourth quarter and 46% for the full year. TD Cowen lifted its price target to $21.00 after the company’s pre-announced positive quarter. Piper Sandler reiterated an Overweight rating with a $20.00 price target, highlighting expected clonoSEQ volume growth of more than 30%, as well as expanding margins and reimbursement tailwinds in the MRD area.
Separately, InvestingPro analysis included ADPT among stocks that appear overvalued relative to their Fair Value, placing it on a list of names classified as most overvalued.
What the filings show
The disclosed trades were executed as part of standard insider reporting. The sales were carried out through the 10b5-1 plan, and the options exercises reflect the conversion of previously granted equity awards into common shares at the stated strike prices. The filings provide the raw transaction details but do not offer additional commentary on the motivations behind the transactions.
Further research
Investors seeking expanded company analysis can access a Pro Research Report on ADPT, one of more than 1,400 U.S. equities covered with in-depth analysis and data.
Bottom line
The combination of insider selling under a 10b5-1 plan and concurrent option exercises comes against the backdrop of a quarter that beat expectations and prompted analyst price-target increases driven by MRD growth metrics. At the same time, third-party valuation work cited in market coverage flags the stock as potentially overvalued, while the share price shows a strong 12-month gain alongside year-to-date weakness.